 |
PDBsum entry 4gaj
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Immune system
|
PDB id
|
|
|
|
4gaj
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
J Virol
86:12923-12932
(2012)
|
|
PubMed id:
|
|
|
|
|
| |
|
Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.
|
|
J.A.Potter,
A.M.Owsianka,
N.Jeffery,
D.J.Matthews,
Z.Y.Keck,
P.Lau,
S.K.Foung,
G.L.Taylor,
A.H.Patel.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The E2 envelope glycoprotein of hepatitis C virus (HCV) binds to the host entry
factor CD81 and is the principal target for neutralizing antibodies (NAbs). Most
NAbs recognize hypervariable region 1 on E2, which undergoes frequent mutation,
thereby allowing the virus to evade neutralization. Consequently, there is great
interest in NAbs that target conserved epitopes. One such NAb is AP33, a mouse
monoclonal antibody that recognizes a conserved, linear epitope on E2 and
potently neutralizes a broad range of HCV genotypes. In this study, the X-ray
structure of AP33 Fab in complex with an epitope peptide spanning residues 412
to 423 of HCV E2 was determined to 1.8 Å. In the complex, the peptide adopts a
β-hairpin conformation and docks into a deep binding pocket on the antibody.
The major determinants of antibody recognition are E2 residues L413, N415, G418,
and W420. The structure is compared to the recently described HCV1 Fab in
complex with the same epitope. Interestingly, the antigen-binding sites of HCV1
and AP33 are completely different, whereas the peptide conformation is very
similar in the two structures. Mutagenesis of the peptide-binding residues on
AP33 confirmed that these residues are also critical for AP33 recognition of
whole E2, confirming that the peptide-bound structure truly represents AP33
interaction with the intact glycoprotein. The slightly conformation-sensitive
character of the AP33-E2 interaction was explored by cross-competition analysis
and alanine-scanning mutagenesis. The structural details of this neutralizing
epitope provide a starting point for the design of an immunogen capable of
eliciting AP33-like antibodies.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |
|